EUVIMEDEUVIMED entdecken
Kohortenstudie

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study

Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki und 10 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02837-8 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Kenji Morimoto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 60…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Immunotherapy. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In Japan, chemoimmunotherapy was approved as treatment for advanced or recurrent non-small-cell lung cancer (NSCLC), including for patients with epidermal growth factor receptor (EGFR) mutations, in December 2018. However, the impact of its approval on real-world clinical outcomes among patients with EGFR-mutant NSCLC remains unclear. The aim of our study was to assess that impact. METHODS: We retrospectively assessed consecutive patients with advanced or recurrent EGFR-mutant NSCLC who received platinum-based cancer therapy after EGFR-tyrosine kinase inhibitors (TKIs) at 20 institutions in Japan from January 2017 to July 2022. RESULTS: We evaluated 120 (27.2%) patients before the chemoimmunotherapy approval and 321 (72.8%) after. Overall, no significant differences in progression-free survival (PFS) or overall survival (OS) were observed between the pre- and post-approval groups (p = 0.72 and p = 0.89, respectively). In the subgroup with programmed cell death-ligand 1 (PD-L1) expression ≥ 50%, the post-approval group had a significantly longer PFS (p = 0.007) and OS (p = 0.048) than the pre-approval group. In contrast, in the PD-L1 < 50% cohort, no significant differences in the PFS (p = 0.54) or OS (p = 0.75) were noted between the groups. CONCLUSIONS: The approval of chemoimmunotherapy did not affect treatment outcomes among patients with EGFR-mutant NSCLC who received platinum-based therapy after EGFR-TKIs. However, patients with high levels of PD-L1 expression had improved outcomes post-approval, suggesting potential benefits in this subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsImmunotherapyHumansMaleFemaleErbB ReceptorsAgedMiddle AgedRetrospective StudiesJapanMutationAdultAged, 80 and overTreatment OutcomeProgression-Free SurvivalB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsEast Asian People

Stichwörter der Autor:innen

EGFR mutationChemoimmunotherapyImmune checkpoint inhibitorNon-small-cell lung cancerPD L1

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. tayamada@koto.kpu-m.ac.jp.
  • Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
  • Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki-shi, Aomori, 036-8562, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, 355-5 Haruobicho, Kamanza-dori Marutamachi-agaru, Kamigyo-ku, Kyoto, 602-8026, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15 749 Honmachi, Higashiyama, Kyoto, 605-0981, Japan.

Zitieren

APA

Morimoto, K., Yamada, T., Furuya, N., Tanaka, H., Yoshimura, A., Oba, T., Hibino, M., Fukuda, T., Goto, Y., Nakao, A., Ogusu, S., Okazaki, Y., Harada, T., Ota, T., Masubuchi, K., Mikami, K., Hata, T., Matsumoto, S., Honda, R., …, & Takayama, K. (2025). Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02837-8

Vancouver

Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, et al. Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02837-8

BibTeX
@article{Morimoto2025,
  author = {Morimoto, Kenji and Yamada, Tadaaki and Furuya, Naoki and Tanaka, Hisashi and Yoshimura, Akihiro and Oba, Tomohiro and Hibino, Makoto and Fukuda, Takahito and Goto, Yasuhiro and Nakao, Akira and Ogusu, Shinsuke and Okazaki, Yuta and Harada, Taishi and Ota, Takayo and Masubuchi, Ken and Mikami, Koji and Hata, Tae and Matsumoto, Shoki and Honda, Ryoichi and Date, Koji and Chihara, Yusuke and Takayama, Koichi},
  title = {Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02837-8}
}
Kostenlos starten →